- In a population-based study of patients with multiple myeloma (MM), long-term survival (LTS) was associated with factors including sociodemographic advantages, lack of comorbidities, upfront stem cell transplantation (SCT), and high patient volume at treatment facility.
Why this matters
- Data regarding LTS in patients with MM are scarce.
- Population-based study to identify patient characteristics in long-term survivors of MM.
- Data source: National Cancer Data Base (NCDB) years 2004-2006.
- Funding: None disclosed.
- 26,986 patients were identified from the NCDB; median OS=2.74 (95% CI, 2.68-2.80) years.
- Patients were grouped according to median OS:
- Group 1 (
- Group 2 (2.74-5.48 years): n=5079.
- Group 3 (5.48-8.22 years): n=3456.
- Group 4 (≥8.22 years): n=4406.
- In multivariate analysis, factors significantly associated with survival of ≥8.22 years vs
- Upfront SCT: Adjusted OR (aOR)=0.48 (95% CI, 0.43-0.53); P<.001.>
- Treatment at high-volume facility (>30 vs
- Insured vs uninsured status: aOR=0.57 (95% CI, 0.45-0.71); P<.001.>
- Charlson Comorbidity Index 0 vs ≥2: aOR=0.30 (95% CI, 0.24-0.37); P<.001.>
- NCDB data did not include tumor stage, cytogenetics.